9e14623a16
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-04-29-9amhealth-waltz-novo-dte-glp1-access-2026.md - Domain: health - Claims: 0, Entities: 1 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
26 lines
No EOL
950 B
Markdown
26 lines
No EOL
950 B
Markdown
# Waltz Health
|
|
|
|
**Type:** Healthcare access platform
|
|
**Domain:** GLP-1 direct-to-employer distribution
|
|
**Status:** Active (as of 2026-01)
|
|
|
|
## Overview
|
|
|
|
Waltz Health operates a direct-to-employer (DTE) access program for FDA-approved obesity medications, partnering with Novo Nordisk to bypass traditional PBM intermediation.
|
|
|
|
## Timeline
|
|
|
|
- **2026-01-01** — Launched DTE access program for FDA-approved obesity medications in partnership with Novo Nordisk
|
|
|
|
## Business Model
|
|
|
|
DTE channel for GLP-1 access, competing with traditional PBM distribution. No enrollment data or market penetration disclosed as of Q1 2026.
|
|
|
|
## Market Position
|
|
|
|
Part of the emerging manufacturer-direct distribution strategy alongside Eli Lilly's Employer Connect and 9amHealth's No-Barriers Bundle. Expert consensus characterizes DTE as 'incremental governance shift, not structural PBM displacement.'
|
|
|
|
## Sources
|
|
|
|
- HR Brew, December 2025
|
|
- PR Newswire, January 2026 |